0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lung cancer is the leading cause of mortality worldwide. Non-small cell lung cancer (NSCLC) is a particularly aggressive cancer, the optimum management of which is still being determined. In the metastatic disease, the standard therapy is a platinum-based combination chemotherapy; however, in spite of available treatment options for patients who progress beyond first-line therapy, prognosis remains poor. Angiogenesis is a tightly regulated process which comprises a complex, complementary, and overlapping network. Inhibition of tumor-related angiogenesis has become an attractive target for anticancer therapy. Antiangiogenic strategy includes: monoclonal antibodies against vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR), small molecule inhibitors of VEGF tyrosine kinase activity, VEGF Trap, and a new class named “vascular disrupting agents,” tested in ongoing clinical trials which will further define their role in the management of NSCLC. BIBF 1120 is an investigational orally administered receptor tyrosine kinase inhibitor that has shown antiangiogenic and antineoplastic activity, inhibiting VEGFR, platelet-derived growth factor receptor, and fibroblast growth factor receptor tyrosine kinases, preventing tumor growth and interfering with the angiogenesis-signaling cascade and overcoming drug resistances.

          Related collections

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2011
          2011
          17 November 2011
          : 7
          : 429-440
          Affiliations
          [1 ]Oncological-Pulmonary Unit 1st, San Camillo Hospital, Rome, Italy
          [2 ]Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
          Author notes
          Correspondence: Filippo de Marinis, Oncological Pulmonary Unit 1st, San Camillo-Forlanini, High Specialization Hospitals, Flajani Pavilion (2nd floor), Cir.ne Gianicolense 87, 00151, Rome, Italy, Tel +39 06 5870 4670, Fax +39 06 5870 4670, Email fdemarinis@ 123456scamilloforlanini.rm.it
          Article
          tcrm-7-429
          10.2147/TCRM.S22079
          3253753
          22241943
          © 2011 Gori et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Review

          Medicine

          fgf, angiogenesis, nsclc, oral antiangiogenic agents, vegf, pdgf

          Comments

          Comment on this article